Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Comment by Trippedstockson Feb 13, 2021 5:28pm
149 Views
Post# 32562932

RE:RE:UCSF - Medical Center

RE:RE:UCSF - Medical Center
yes, it may be a stretch, but the big stretch is people thinking phase 3 results are coming tomorrow, or the day after, maybe Tuesday.... No Jan 25, no after the bought deal....

The companies investors deck is showing this to be Q1-2021. I think the company knows what quarter they are in. I don't care that they filed year end in June, that was pandemic delay on reporting and wouldn't change the current quarter. Or 2020 had 6 quarters. The prospectus distribution of funds clearly states $2,000,000 will be spent in Q1-2021 to complete the 210 interm analysis. $4,000,000 in Q2-2021 for the next 200(400 interm analysis). No mention of the 400 starting this quarter. Now if it costs $4,000,000 for the next 200 people it would be safe to assume the first 210 would cost $4,000,000. Half the cost to complete would indicate half the amount of people treated (100ish). Or if we are in Q3-2021 as the "DD king" on Ihub says, we've been owing $6 million for the last 7 months and have 400 people enrolled and the 210 analysis has been completed and dosage level determined... My scenario for EAP is the only way we see results before the end of Q1. As the prospectus states in the recent developments - Bucillamine "it is estimated that over 200 patients will have completed the study for the interim analysis by the end of the second quarter of 2021."

Now why would, in December, MF say we would be applying for EUA? EUA application is 6 months away? Wouldn't you need results to display its efficacy? So we wait till end of June for the 210 interm analysis? Slice it, dice it, anyway you want. There is not mild-mod PH 3 results coming next week as people think. We need EAP for the "space shuttle mission". We are still going through mock pre-launch sequence back in the hanger and aren't even transporting to the launch pad.

Sorry folks.
<< Previous
Bullboard Posts
Next >>